ALK and neuroblastoma: Altogether, these data suggest that upon treatment with the recently described ALK TKI repotrectinib, growth of ALK-driven neuroblastoma cells and xenografts are inhibited, suggesting that repotrectinib should be further explored in a neuroblastoma setting.